Cancer Cell
Volume 26, Issue 3, 8 September 2014, Pages 428-442
Journal home page for Cancer Cell

Article
BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

https://doi.org/10.1016/j.ccr.2014.07.006Get rights and content
Under an Elsevier user license
open archive

Highlights

  • BCR-ABL1 compound mutations can lead to clinical failures of ponatinib and other TKIs

  • Nearly all non-T315I compound mutants are sensitive to at least one approved TKI

  • T315I-inclusive compound mutants confer resistance to all TKIs, including ponatinib

  • Structural modeling provides a basis for design of TKIs targeting compound mutants

Summary

Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph+) leukemia, including the recalcitrant BCR-ABL1T315I mutant. However, emergence of compound mutations in a BCR-ABL1 allele may confer ponatinib resistance. We found that clinically reported BCR-ABL1 compound mutants center on 12 key positions and confer varying resistance to imatinib, nilotinib, dasatinib, ponatinib, rebastinib, and bosutinib. T315I-inclusive compound mutants confer high-level resistance to TKIs, including ponatinib. In vitro resistance profiling was predictive of treatment outcomes in Ph+ leukemia patients. Structural explanations for compound mutation-based resistance were obtained through molecular dynamics simulations. Our findings demonstrate that BCR-ABL1 compound mutants confer different levels of TKI resistance, necessitating rational treatment selection to optimize clinical outcome.

Cited by (0)

27

Co-first author

28

Co-senior author